Treatment for patients with BRAFV600E mutant metastatic colorectal cancer
Official title: A Multicenter, Retrospective, Observational Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
Run by Fudan University · NCT06749015 · Data updated 2026-11-12
This study looks at how well current treatments work for patients in China with advanced colorectal cancer that has a specific BRAFV600E mutation.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Fudan University Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | March 1, 2021 |
| Main results expected | October 1, 2025 |
| Study ends | October 1, 2026 |
| Registry record updated | December 27, 2024 |
| Trial ID | NCT06749015 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients diagnosed with unresectable metastatic colorectal cancer who have a confirmed BRAFV600E mutation.
✕Probably not a fit
Patients with previous chronic inflammatory bowel disease, chronic diarrhea, recurrent bowel obstruction, or symptomatic brain metastases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to investigate the mutation rate, treatment patterns, effectiveness, and safety of current treatment regimens for patients with BRAFV600E mutant metastatic colorectal cancer (mCRC) in China. It will collect real-world data from multiple centers to better understand the prognosis and survival outcomes for this specific patient population. The study focuses on patients who have been diagnosed with unresectable metastatic colorectal cancer and have confirmed BRAFV600E mutations in their tumor tissue.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into effective treatment strategies for patients with BRAFV600E mutant mCRC, potentially improving their survival outcomes.
How similar studies have gone: Other studies have shown varying success in understanding treatment patterns for mutant mCRC, but this specific focus on the BRAFV600E mutation in the Chinese population is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of histologically or cytologically confirmed CRC that is metastatic and unresectable * Presence of BRAFV600E mutation in tumor tissue, as confirmed by a local assay Exclusion Criteria: * patients with previous chronic inflammatory bowel disease, chronic diarrhea or recurrent bowel obstruction patients with symptomatic brain metastases active clinical severe infection
Where it's running
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Becotatug Vedotin plus Pucotenlimab for EGFR-positive metastatic colorectal cancer
This study tests whether combining becotatug vedotin with pucotenlimab can shrink tumors in adults with colorectal cancer that has returned or spread after at least two prior treatments and whose tumors express EGFR.
-
DEM301 in advanced colorectal cancer: a first-in-human test
This first-in-human Phase 1 study tests DEM301 in adults with advanced metastatic colorectal cancer to see if it is safe, how it behaves in the body, and whether it shows any signs of activity.
-
Immunotherapy plus Simvastatin and Targeted Therapy with Chemotherapy for Advanced Colorectal Cancer
This trial tests whether adding immune therapy (adbelimumab? actually Adebrelimab) with simvastatin and targeted therapy to standard chemotherapy helps people with metastatic colorectal cancer that is MSI-H/dMMR or MSS/pMMR depending on combination.
-
Fruquintinib treatment in adults with metastatic colorectal cancer in Poland
This study looks at whether taking fruquintinib by mouth after prior therapies helps adults with metastatic colorectal cancer in Poland live longer before the cancer progresses and overall survival, while also considering quality of life.
-
Understanding why BRAF V600E colorectal cancer stops responding to targeted therapy
This study tests why metastatic colorectal cancer with a BRAF V600E mutation stops responding to encorafenib and cetuximab, by collecting tissue, blood, and stool samples over time.
-
Second-line combination treatment for MSS metastatic colorectal cancer
This trial will try folinic acid plus continuous 5-FU with liposomal irinotecan, sometimes combined with cetuximab or bevacizumab, as a second-line option for adults with MSS metastatic colorectal cancer who progressed on or cannot tolerate oxaliplatin-based therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.